Ultragenyx Pharmaceutical Inc (RARE)
41.90
-0.71
(-1.67%)
USD |
NASDAQ |
May 17, 16:00
41.90
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Enterprise Value: 3.069B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 3.069B |
| May 16, 2024 | 3.130B |
| May 15, 2024 | 3.006B |
| May 14, 2024 | 2.994B |
| May 13, 2024 | 2.993B |
| May 10, 2024 | 2.988B |
| May 09, 2024 | 3.015B |
| May 08, 2024 | 3.043B |
| May 07, 2024 | 3.076B |
| May 06, 2024 | 3.163B |
| May 03, 2024 | 3.142B |
| May 02, 2024 | 3.179B |
| May 01, 2024 | 3.188B |
| April 30, 2024 | 3.124B |
| April 29, 2024 | 3.247B |
| April 26, 2024 | 3.266B |
| April 25, 2024 | 3.233B |
| April 24, 2024 | 3.269B |
| April 23, 2024 | 3.338B |
| April 22, 2024 | 3.219B |
| April 19, 2024 | 3.109B |
| April 18, 2024 | 3.193B |
| April 17, 2024 | 3.254B |
| April 16, 2024 | 3.104B |
| April 15, 2024 | 3.151B |
| Date | Value |
|---|---|
| April 12, 2024 | 3.494B |
| April 11, 2024 | 3.801B |
| April 10, 2024 | 3.876B |
| April 09, 2024 | 3.789B |
| April 08, 2024 | 3.762B |
| April 05, 2024 | 3.763B |
| April 04, 2024 | 3.500B |
| April 03, 2024 | 3.500B |
| April 02, 2024 | 3.459B |
| April 01, 2024 | 3.491B |
| March 31, 2024 | 3.468B |
| March 28, 2024 | 3.267B |
| March 27, 2024 | 3.278B |
| March 26, 2024 | 3.166B |
| March 25, 2024 | 3.162B |
| March 22, 2024 | 3.198B |
| March 21, 2024 | 3.264B |
| March 20, 2024 | 3.293B |
| March 19, 2024 | 3.293B |
| March 18, 2024 | 3.259B |
| March 15, 2024 | 3.323B |
| March 14, 2024 | 3.264B |
| March 13, 2024 | 3.420B |
| March 12, 2024 | 3.347B |
| March 11, 2024 | 3.417B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.201B
Minimum
Mar 16 2020
10.97B
Maximum
Dec 23 2020
3.694B
Average
3.124B
Median
Enterprise Value Benchmarks
| Insulet Corp | 13.77B |
| Sarepta Therapeutics Inc | 12.27B |
| FibroGen Inc | 55.95M |
| Apellis Pharmaceuticals Inc | 4.781B |
| Amylyx Pharmaceuticals Inc | -248.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -170.68M |
| Revenue (Quarterly) | 108.83M |
| Total Expenses (Quarterly) | 274.18M |
| EPS Diluted (Quarterly) | -2.03 |
| Gross Profit Margin (Quarterly) | 83.89% |
| Profit Margin (Quarterly) | -156.8% |
| Earnings Yield | -19.18% |
| Normalized Earnings Yield | -19.27 |